Home » Topics » Regulatory » EMA

EMA
RSS

EMA gives positive opinion to Gilead Sciences' Vosevi

June 26, 2017

EMA validates Veyvondi MAA

June 22, 2017

EMA accepts Novartis' MAA filing for erenumab

June 22, 2017

Tarix Orphan's TXA-127 granted orphan drug status in E.U. for epidermolysis bullosa

June 13, 2017

Hemophilia A gene therapy from Sangamo and Pfizer receives E.U. orphan drug designation

June 7, 2017

EMA's COMP recommends orphan medicinal product designation for Catalyst Biosciences' CB-2679d

June 1, 2017

Dasiglucagon receives positive opinion for designation as orphan medicinal product

May 30, 2017

EMA grants PRIME designation for asunercept as treatment of glioblastoma

May 30, 2017

Myrcludex B granted EMA PRIME eligibility

May 26, 2017

EMA awards orphan drug designation to Actinium's Actimab-A

May 25, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...